<DOC>
	<DOCNO>NCT02603926</DOCNO>
	<brief_summary>The purpose study examine safety efficacy Allopregnanolone possible treatment symptom Fragile X-associated Tremor/Ataxia Syndrome ( FXTAS ) .</brief_summary>
	<brief_title>Treatment Fragile-X Associated Tremor/Ataxia Syndrome ( FXTAS ) With Allopregnanolone</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Pregnanolone</mesh_term>
	<criteria>Inclusion Criteria Fragile X premutation carrier status ( 55 200 CGG repeat FMR1 ) , Diagnosis FXTAS include intention tremor and/or ataxia and/or deficit BDS2 demonstrate executive function deficit . Exclusion Criteria genetic problem addition premutation history significant brain trauma significant substance abuse inability follow protocol liver kidney disease heart failure active cancer serious systemic disease current use phenytoin</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>